Abstract
Citing heightened interest in repatriating active pharmaceutical ingredient (API) production from Asia to Europe, Dottikon Exclusive Synthesis says it is set to launch a new multipurpose API plant and is studying the addition of pilot-scale production and spray-drying capacity. The pharmaceutical services firm wants to invest $660 million over the next 10 years at its site in Dottikon, Switzerland, adding about 100 jobs, according to reporting in Blick , a Swiss newspaper.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
